Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant hepatitis B lentiviral vector
- Development stage
- Unknown
- Lead developer
- Xiamen Innovax Biotech
- Modality
- Recombinant Proteins and Enzymes, Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
Recombinant hepatitis B lentiviral vector is an investigational gene therapy designed to treat chronic hepatitis B virus (HBV) infection. This therapy uses a replication-deficient lentiviral vector engineered to deliver genetic material targeting HBV, with the aim of inhibiting viral replication in hepatocytes. Lentiviral vectors are commonly used in gene therapy due to their ability to stably integrate therapeutic genes into host cell genomes, enabling long-term expression. The approach leverages RNA interference or other genetic mechanisms delivered by the vector to suppress HBV activity within infected liver cells[4][5][2]. Early-phase clinical trials have been initiated to evaluate its safety, tolerability, and initial efficacy in patients with chronic HBV infection[2].
- Other names
- recombinant therapeutic hepatitis B lentiviral vector injection
02
Targets
CD4 (T lymphocyte surface antigen)
Beyond the preview
Go deeper on recombinant hepatitis B lentiviral vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant hepatitis B lentiviral vector.